verekitug — Clinical data readout
H2 2027
Data are expected in the second half of 2027, and the Company believes that these analyses will provide important insights into the potential clinical impact of verekitug in COPD.Source filing
UPB biotech catalysts & pipeline
UPSTREAM BIO INC · Data as of 2026-10-25
Upcoming catalysts
verekitug — Clinical data readout
H2 2027
Data from the study are expected in the second half of 2027.Source filing
verekitug — NDA/BLA submission
2030
With supportive Phase 3 results, the Company expects to submit a Biologics License Application (BLA) to the FDA for both indications, which could enable potential launch as early as 2030.Source filing